View On Demand

Disruptive Technology Will Transform the Treatment of Back Pain

About the Event

Back pain is the number one cause of disability around the world. Epidural steroid injections can offer some relief, but often need to be delivered far too frequently, with patients visiting their physicians every 30 days or less in pursuit of a pain-free back. SpineThera has developed a sustained release, microsphere delivery platform that outpaces all currently available epidural injectable steroids on two fronts:

  • Clinical trials show SpineThera microsphere technology provides relief for 60 to 90 days with 71% of respondents reporting a 50% or greater reduction in pain after 60 days.
  • Because the microspheres are so small (1/2 the size of a red blood cell), SpineThera’s formulation can contain 50 times higher drug concentrations, meaning treatments can be precision targeted.

SpineThera has completed a Phase 1/2 clinical trial in Australia with the unprecedented results mentioned above. They are in talks with the FDA to move forward with trials in the US.

Long term, this is a platform technology with multiple high value applications beyond back pain. SpineThera’s has a robust patent portfolio protecting the microsphere delivery system.

View On-Demand


All statements and expressions are the sole opinion of the company and are subject to change without notice. The Company is not liable for any investment decisions by its readers or subscribers. It is strongly recommended that any purchase or sale decision be discussed with a financial advisor, or a broker-dealer, or a member of any financial regulatory bodies. The information contained herein has been provided as an information service only. The accuracy or completeness of the information is not warranted and is only as reliable as the sources from which it was obtained. Investors are cautioned that they may lose all or a portion of their investment in this or any other company. Information contained herein contains “forward looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities and Exchange Act of 1934, as amended. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, goals, assumptions or future events or performance are not statements of historical facts and may be “forward looking statements”. Forward looking statements are based on expectations, estimates and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of words such as “expects”, “will”, “anticipates”, “estimates”, “believes”, or by statements indicating certain actions “may”, “could”, “should” or “might” occur.